Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride may cause mental fog, vision blurriness, and sleep issues. Users suggest trying topical versions of the drug to mitigate side effects.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

Combining finasteride with dutasteride may have additive benefits for reducing scalp DHT, but the extent is unknown. Some users report less shedding when using both treatments, with variations in dosage and application methods.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

Whether using both Fluridil and Alfatradiol together could be more effective than either one alone as a hair loss treatment, given their different mechanisms of action.

Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.

Low doses of finasteride, even as low as 0.25 mg, can effectively prevent hair loss without significantly lowering DHT levels. Combining finasteride with natural DHT-lowering solutions may achieve similar results to higher doses.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The user reports that using topical Dutasteride has stopped their hair loss, and they are curious about potential side effects and regrowth. They also mention having scalp psoriasis and past SSRI use affecting libido.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

A user experienced sexual side effects, including reduced semen production and numbness, after switching from finasteride to dutasteride for hair loss. They decided to stop dutasteride to prioritize their sexual health and may return to finasteride if issues resolve.

Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.

The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.

The user has been using finasteride for 15 years but is noticing increased hair loss. They are considering increasing the finasteride dosage or switching to dutasteride but are concerned about side effects; they previously stopped using minoxidil due to heart palpitations.

The user experienced significant hair regrowth after switching from finasteride and minoxidil to dutasteride. They believe dutasteride is highly effective for treating hair loss.

A 22-year-old with advanced diffuse thinning is considering oral dutasteride after stopping finasteride due to side effects like brain fog and testicular pain. They are also contemplating a hair transplant combined with oral dutasteride and topical finasteride, noting a thick donor area.

Finasteride users have mixed experiences with creatine; some experience increased hair loss, while others do not. Finasteride's DHT-blocking effects might counteract any DHT increase from creatine, but individual responses vary.

The conversation discusses using Dutasteride, oral Minoxidil, and other medications for hair loss, with the user expressing satisfaction despite potential side effects. The user prefers these treatments to maintain a youthful hairline, despite others suggesting alternative methods.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

Creatine might speed up hair loss in those prone to male pattern baldness, possibly due to increased DHT levels. Some users experience no issues when using creatine with treatments like finasteride, minoxidil, or dutasteride.

The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.

The user shared a 2.5-year hair regrowth update using dutasteride, minoxidil foam, a 1.5mm roller, nizoral shampoo, biotin, multivitamins, and a healthy lifestyle, reporting noticeable regrowth after a year with no side effects. The user uses generic dutasteride and Kirkland multivitamins.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

The user is using Dutasteride (90.5mg) and Minoxidil (2.5mg) for hair loss since October 2025 and is seeking feedback on their progress. They provided comparison photos from October 2025 and January 2026.